FDA Approves Ulcerative Colitis Indication for J&J's Remicade

Drug Industry Daily
KEYWORDS Drug Approvals / FDA
A A

Johnson & Johnson’s (J&J) blockbuster arthritis drug Remicade has been approved in the U.S. to treat ulcerative colitis (UC), an indication that could expand the drug’s market by roughly 20 percent.

To View This Article:

Login

Subscribe To Drug Industry Daily